Cancer Clinical Investigation

Search results

• Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

  Levine, J.

  10/12/24

  1 item of Media coverage

  Press/Media

• Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

  Mascarenhas, J.

  10/12/24

  8 items of Media coverage

  Press/Media

• Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease

  Levine, J.

  10/12/24

  1 item of Media coverage

  Press/Media

• Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

  Levine, J.

  10/12/24

  1 item of Media coverage

  Press/Media

• Icahn School of Medicine at Mount Sinai Researchers Describe New Findings in Eczema (Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report)

  Tiersten, A. & Gulati, N.

  9/12/24

  1 item of Media coverage

  Press/Media

• Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

  Levine, J.

  9/12/24

  1 item of Media coverage

  Press/Media

• New York Proton Center Researcher Highlights Research in Carcinomas (The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies)

  Bakst, R.

  9/12/24

  1 item of Media coverage

  Press/Media

• Novel MDM2 Inhibitor Shows Disease-Modifying Activity in R/R Myelofibrosis; Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

  Mascarenhas, J.

  9/12/24

  1 item of Media coverage

  Press/Media

• Novel MDM2 Inhibitor Shows Disease-Modifying Activity in R/R Myelofibrosis

  Mascarenhas, J.

  9/12/24

  1 item of Media coverage

  Press/Media

• Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL

  Levine, J.

  9/12/24

  2 items of Media coverage

  Press/Media

• Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

  Mascarenhas, J.

  8/12/24

  1 item of Media coverage

  Press/Media

• Weekly: Tilray Brands (TLRY: $1.28) shares post worst week in three weeks; -6c [4.5%]

  Kaplan,, S. & Sfakianos, J.

  7/12/24

  1 item of Media coverage

  Press/Media

• Weekly: Karyopharm Therapeutics (KPTI: 76.82c) sinks 9% on weak volume, Cash Runway of 4 months; -7.69c [9.1%]

  Mascarenhas, J.

  7/12/24

  1 item of Media coverage

  Press/Media

• Ajax Therapeutics to Present Overview of Phase 1 Clinical Trial Evaluating AJ1-11095

  Mascarenhas, J.

  6/12/24

  1 item of Media coverage

  Press/Media

• Pelabresib and Ruxolitinib Achieve Primary End Point in Phase 3 MANIFEST-2 Trial

  Mascarenhas, J.

  5/12/24

  1 item of Media coverage

  Press/Media

• Ajax Therapeutics to Present Overview of Phase 1 Clinical Trial Evaluating AJ1-11095

  Mascarenhas, J.

  5/12/24

  1 item of Media coverage

  Press/Media

• Genes highlight who will benefit from multiple myeloma therapy

  Laganà, A.

  4/12/24 → 5/12/24

  2 items of Media coverage

  Press/Media

• Genes Highlight Who'll Benefit From Multiple Myeloma Treatment With Venclexta

  Laganà, A.

  4/12/24

  7 items of Media coverage

  Press/Media

• Researchers from University of Texas Southwestern Medical Center Detail Findings in COVID-19 (Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed Sars-cov-2 Infections)

  Hirsch, F., Hirsch, F., Bhalla, S. & Krammer, F.

  4/12/24

  1 item of Media coverage

  Press/Media

• Genes Highlight Who'll Benefit From Multiple Myeloma Therapy

  Laganà, A.

  4/12/24

  45 items of Media coverage

  Press/Media

• Ajax Therapeutics to Present Overview of Phase 1 Clinical Trial Evaluating AJ1-11095

  Mascarenhas, J.

  4/12/24

  1 item of Media coverage

  Press/Media

• A case of adult ETV6-ASCL6 fusion gene positive chronic myeloproliferative tumor and literature review.

  Wang, P.

  3/12/24

  1 item of Media coverage

  Press/Media

• Ajax Therapeutics to Present Overview of Phase 1 Clinical Trial Evaluating AJ1 11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis at the American Society of Hematology Annual Meeting

  Mascarenhas, J.

  2/12/24 → 3/12/24

  3 items of Media coverage

  Press/Media

• Tilray Brands falls 24% in past year

  Kaplan,, S. & Sfakianos, J.

  3/12/24

  1 item of Media coverage

  Press/Media

• Karyopharm Therapeutics adds 24% in past year

  Mascarenhas, J.

  3/12/24

  1 item of Media coverage

  Press/Media